European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: Endorsing organization: European Society of Endocrinology
- PMID: 32026626
- DOI: 10.1111/andr.12770
European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: Endorsing organization: European Society of Endocrinology
Abstract
Background: Evidence regarding functional hypogonadism, previously referred to as 'late-onset' hypogonadism, has increased substantially during the last 10 year.
Objective: To update the European Academy of Andrology (EAA) guidelines on functional hypogonadism.
Methods: Expert group of academicians appointed by the EAA generated a series of consensus recommendations according to the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) system.
Results: The diagnosis of functional hypogonadism should be based on both the presence of clinical symptoms supported by repeatedly low morning fasting serum total testosterone (T) measured with a well-validated assay, after exclusion of organic causes of hypogonadism. Lifestyle changes and weight reduction should be the first approach in all overweight and obese men. Whenever possible, withdrawal/modification of drugs potentially interfering with T production should be advised. Testosterone replacement therapy (TRT) is contraindicated in men with untreated prostate or breast cancer, as well as severe heart failure. Severe low urinary tract symptoms and haematocrit >48%-50% represent relative contraindications for TRT. Prostate-specific antigen and digital rectal examination of the prostate should be undertaken in men >40 years of age before initiating TRT to exclude occult prostate cancer. Transdermal T should be preferred for initiation of TRT, whereas gonadotrophin therapy is only recommended when fertility is desired in men with secondary hypogonadism. TRT is able to improve sexual function in hypogonadal men. Other potential positive outcomes of TRT remain uncertain and controversial.
Conclusion: TRT can reliably improve global sexual function in men with hypogonadism in the short term. Long-term clinical benefits, and safety of TRT in functional hypogonadism, remain to be fully documented. Clinicians should therefore explicitly discuss the uncertainties and benefits of TRT and engage them in shared management decision-making.
Keywords: cardiovascular risk; erectile dysfunction; functional hypogonadism; late-onset hypogonadism; libido; obesity; testosterone.
© 2020 American Society of Andrology and European Academy of Andrology.
Similar articles
-
EMAS position statement: Testosterone replacement therapy in older men.Maturitas. 2023 Dec;178:107854. doi: 10.1016/j.maturitas.2023.107854. Epub 2023 Oct 15. Maturitas. 2023. PMID: 37845136
-
Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE).J Endocrinol Invest. 2022 Dec;45(12):2385-2403. doi: 10.1007/s40618-022-01859-7. Epub 2022 Aug 26. J Endocrinol Invest. 2022. PMID: 36018454 Free PMC article.
-
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.J Clin Endocrinol Metab. 2018 May 1;103(5):1715-1744. doi: 10.1210/jc.2018-00229. J Clin Endocrinol Metab. 2018. PMID: 29562364
-
Testosterone Therapy: What We Have Learned From Trials.J Sex Med. 2020 Mar;17(3):447-460. doi: 10.1016/j.jsxm.2019.11.270. Epub 2020 Jan 9. J Sex Med. 2020. PMID: 31928918 Review.
-
The Optimal Indication for Testosterone Replacement Therapy in Late Onset Hypogonadism.J Clin Med. 2019 Feb 7;8(2):209. doi: 10.3390/jcm8020209. J Clin Med. 2019. PMID: 30736442 Free PMC article. Review.
Cited by
-
[Testosterone replacement therapy and possible side effects].Urologie. 2024 Oct 10. doi: 10.1007/s00120-024-02455-8. Online ahead of print. Urologie. 2024. PMID: 39390141 Review. German.
-
Every Third Male Patient with Acromegaly Recovers from Hypogonadism after Neurosurgical Treatment.J Clin Med. 2024 Sep 18;13(18):5526. doi: 10.3390/jcm13185526. J Clin Med. 2024. PMID: 39337013 Free PMC article.
-
Testosterone deficiency and chronic kidney disease.J Clin Transl Endocrinol. 2024 Aug 14;37:100365. doi: 10.1016/j.jcte.2024.100365. eCollection 2024 Sep. J Clin Transl Endocrinol. 2024. PMID: 39253627 Free PMC article. Review.
-
The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation.Health Technol Assess. 2024 Aug;28(43):1-210. doi: 10.3310/JRYT3981. Health Technol Assess. 2024. PMID: 39248210 Free PMC article.
-
Evaluating the impact of testosterone replacement therapy on carotid atherosclerosis: a systematic review and meta-analysis.Future Sci OA. 2024 Dec 31;10(1):2365125. doi: 10.1080/20565623.2024.2365125. Epub 2024 Aug 25. Future Sci OA. 2024. PMID: 39183456 Free PMC article. Review.
References
REFERENCES
-
- Wang C, Nieschlag E, Investigation SR, et al. treatment and monitoring of late-onset hypogonadism in males. Int J Androl. 2009;32:1-10.
-
- Yeap BB, Wu FCW. Clinical practice update on testosterone therapy for male hypogonadism: contrasting perspectives to optimise care. Clin Endocrinol (Oxf). 2019;90:56-65.
-
- Tajar A, Forti G, O'Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010;95:1810-1818.
-
- Grossmann M, Matsumoto AM. A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. J Clin Endocrinol Metab. 2017;102:1067-1075.
-
- Bhasin S, Brito JP, Cunningham GR, et al. testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103:1715-1744.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources